RCKT logo

RCKT Rocket Pharmaceuticals Inc

$2.61
$0.00
(0.00%)
Pre-Market
56

Bullish Sentiment

How do you feel about RCKT?

Loading...
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
Zacks
This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Analysts upgraded Similarweb, Rocket Pharmaceuticals, Radiant Logistics and Ulta Beauty; Paychex rose to Peer Perform, with targets raised.read more...
Benzinga
Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock
Needham said the FDA outcome was better than expected because the regulator could have demanded meaningful changes to Rocket’s Danon disease trial.
Stocktwits
Rocket Pharma Gets FDA Alignment On This Key Trial -- A Look At Some Key Highlights
The FDA confirmed continued enrollment and dosing under the modified trial protocol after reviewing safety data from the first three patients treated at the recalibrated dose.
Stocktwits
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced alignment with the U.S. Food and Drug Administration (FDA) on...
Business Wire
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
AtaiBeckley Inc (ATAI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?
Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today announced that the Company will participate in the 2026 Cantor Global...
Business Wire